Enanta Pharmaceuticals Inc
ENTA
Market Cap$276.6M
Close$
$-8.31
168.5% downside
Current Fair Value
168.5% downsideOvervalued by 168.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $276.60 Million |
|---|---|
| Enterprise Value | $-23,707,036.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-6.25 |
| Beta | 1.03 |
| Outstanding Shares | 21,179,400 |
| Avg 30 Day Volume | 130,492 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.1 |
|---|---|
| PEG | 12.16 |
| Price to Sales | 4.04 |
| Price to Book Ratio | 1.73 |
| Enterprise Value to Revenue | -0.33 |
| Enterprise Value to EBIT | 0.18 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly